All In MedTech

Device Trial Radar · NCT06380075

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 29, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 23, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this research study is to compare two ultrawide field cameras to the gold standard imaging system to evaluate the back of the eye. The main question it aims to answer is the same results and information can be acquired from all of the cameras for evaluating and monitoring inherited retinal diseases (IRDs). Participants will: * undergo pupillary dilation * have photographs taken of the inside of the eyes using three different cameras

Conditions

  • Retinal Disease

Interventions

  • Spectralis FAF imagingDevice

    Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.

  • Optos imagingDevice

    Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.

  • Clarus imagingDevice

    Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare FAF retinal patterns by Clarus and standard Spectralis FAF imagingTime frame: Up to 2 hours
  2. Compare FAF retinal patterns by Optos and standard Spectralis FAF imagingTime frame: Up to 2 hours
  3. Compare FAF retinal patterns by Clarus and Optos FAF imagingTime frame: Up to 2 hours

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Ophthalmology and Visual Sciences

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.